Genetype Commercial Integration Completion
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced the completion of the geneType commercial capability integration, which includes the restoration of essential commercial processes and partnerships. The integration allows Rhythm to offer the complete geneType product portfolio and is expected to enhance commercial opportunities for both the ColoSTAT and geneType platforms. Key personnel have been transferred to support the geneType product portfolio, and critical partnerships have been re-established to facilitate service delivery.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Quarterly Activities Report and Appendix 4C - Dec24
- About the Genetype Acquisition
- Completion of Genetype Risk Assessment Portfolio Acquisition
- RHY Acquires Genetype Genetic Risk Assessment Business
- Pause in Trading
Later from Rhythm Biosciences
- RHY Investor Webinar
- RHY Genetype Commercial Sales
- EGM - Investor Presentation
- Quarterly Activities Report and Appendix 4C 31 March 2025
- Breast Cancer Risk Study University of Melbourne
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences